Monopar says Phase 3 trial shows ALXN1840 beats standard care in neurologic Wilson disease

• Monopar reported new Phase 3 FoCus trial analyses showing ALXN1840 delivered greater neurologic benefit than standard of care in Wilson disease patients with neurologic symptoms at baseline.
• Results were presented at American Academy of Neurology Annual Meeting 2026 in a late-breaker oral and poster session.
• Data showed more patients improved and fewer worsened on ALXN1840 versus standard of care through Week 48.
• Long-term follow-up indicated neurologic benefit increased on continued treatment and held up for about 3 years.
• Monopar kept plan for a mid-2026 FDA New Drug Application submission for ALXN1840.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604191900PRIMZONEFULLFEED9692716) on April 19, 2026, and is solely responsible for the information contained therein.